Dr. Yuichiro Ohe Thoracic Oncology

Deputy Director - National Cancer Center Hospital , Experience:

Book Appointment

About Doctor

Dr. Yuichiro Ohe is among the top thoracic oncologist and lung cancer specialist in Tokyo, Japan.

Dr. Yuichiro Ohe is president of the Japanese Society of Medical Oncology (JSMO), a board of director of International Association for the Study of Lung Cancer (IASLC), and a chair of Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. He has been working in NCCH in Tokyo and National Cancer Center Hospital East in Kashiwa since 1989. His research field is development of new treatments for lung cancer including chemotherapy, multidisciplinary treatment, immunotherapy, and translational research.

Thoracic oncology department is consisting of seven staff physicians and residents. The department has approximately 60 beds in the hospital, and a total of more than 400 new patients with lung cancer, malignant mesothelioma, thymic cancer, and thymoma were admitted every year. Research activities of the department can be classified into four categories: (1) phase I and phase II studies to evaluate new anticancer drugs; (2) multi-institutional phase III studies to establish new standard treatments against thoracic malignancy; (3) pharmacokinetic and pharmacodynamic (PK/PD) studies to investigate interpatient variability, optimal administration schedules, and drug–drug interactions; and (4) translational research using clinical samples from bench to bedside or from bedside to bench for the development of innovative treatment strategies.


National Cancer Centre, Japan


  • Thoracic Oncology

Procedures Performed

  • Lung cancer treatment
  • Lung cancer surgery
  • Malignant mesothelioma
  • Thymic cancer
  • Thymoma
  • Thoracic malignancies

Research & Publications

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy